Corynoxine B derivative CB6 prevents Parkinsonian toxicity in mice by inducing PIK3C3 complex-dependent autophagy
Zhou Zhu,Liang-feng Liu,Cheng-fu Su,Jia Liu,Benjamin Chun-Kit Tong,Ashok Iyaswamy,Senthilkumar Krishnamoorthi,Sravan Gopalkrishnashetty Sreenivasmurthy,Xin-jie Guan,Yu-xuan Kan,Wen-jian Xie,Chen-liang Zhao,King-ho Cheung,Jia-hong Lu,Jie-qiong Tan,Hong-jie Zhang,Ju-xian Song,Min Li
DOI: https://doi.org/10.1038/s41401-022-00871-0
IF: 7.169
2022-02-25
Acta Pharmacologica Sinica
Abstract:Increasing evidence shows that autophagy impairment is involved in the pathogenesis and progression of neurodegenerative diseases including Parkinson’s disease (PD). We previously identified a natural alkaloid named corynoxine B (Cory B) as a neuronal autophagy inducer. However, its brain permeability is relatively low, which hinders its potential use in treating PD. Thus we synthesized various derivatives of Cory B to find more potent autophagy inducers with improved brain bioavailability. In this study, we evaluated the autophagy-enhancing effect of CB6 derivative and its neuroprotective action against PD in vitro and in vivo. We showed that CB6 (5–40 μM) dose-dependently accelerated autophagy flux in cultured N2a neural cells through activating the PIK3C3 complex and promoting PI3P production. In MPP+-treated PC12 cells, CB6 inhibited cell apoptosis and increased cell viability by inducing autophagy. In MPTP-induced mouse model of PD, oral administration of CB6 (10, 20 mg· kg−1· d−1, for 21 days) significantly improved motor dysfunction and prevented the loss of dopaminergic neurons in the striatum and substantia nigra pars compacta. Collectively, compound CB6 is a brain-permeable autophagy enhancer via PIK3C3 complex activation, which may help the prevention or treatment of PD.
pharmacology & pharmacy,chemistry, multidisciplinary